Patent ID: 11939368
Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A Fc fusion QTY CCR9 variant receptor protein comprising a Fc domain and a QTY CCR9 variant receptor domain; wherein the QTY CCR9 variant receptor domain comprises a QTY transmembrane region characterized by an alpha helix: and wherein all of the leucines (L) in a transmembrane domain of a wild type CCR9 sequence are replaced with glutamines (Q) and all of the valines (V) in the transmembrane domain of the wild type sequence are replaced with threonines (T) and all of the isoleucines (I) in the transmembrane domain of the wild type sequence are replaced with threonines (T) and all of the phenylalanines (F) in the transmembrane domain of the wild type sequence are replaced with tyrosines (Y).